

Initial Evaluation and Management of Skin Disorders

William Rushton

Joseph M. Grover

William J. Brady

REFERENCES

1. Feldman SR, Fleischer AB, McConnell RC: Most common dermatologic problems identified by internists, 1990–1994. *Arch Intern Med* 158: 726, 1998. [PMID: 9554678]
2. Tan CH, Rasool S, Johnston GA: Contact dermatitis: allergic and irritant. *Clin Dermatol* 32: 117, 2014. [PMID: 24314385]
3. McQueen A, Martin SA, Lio PA: Derm emergencies: detecting early signs of trouble. *J Fam Pract* 61: 71, 2012. [PMID: 22312611]
4. Byer RL, Bachur RG: Clinical deterioration among patients with fever and erythroderma. *Pediatrics* 118: 2450, 2006. [PMID: 17142531]
5. Usatine RP, Riojas M: Diagnosis and management of contact dermatitis. *Am Fam Physician* 82: 3, 2010. [PMID: 20672788]
6. Tharp MD: Cetirizine: a new therapeutic alternative for chronic urticaria. *Cutis* 58: 94, 1996. [PMID: 8823559]
7. Goldsmith P, Dowd PM: The new H₁ antihistamines. *Dermatol Clin* 11: 87, 1993. [PMID: 8094649]
8. Acosta EP, Fletcher CV: Valacyclovir. *Ann Pharmacother* 31: 185, 1997. [PMID: 9034421]
9. Asero R: Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. *Clin Exp Dermatol* 32: 1, 2007. [PMID: 16824053]
10. Lin RY, Curry A, Pesola GR, et al: Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. *Ann Emerg Med* 36: 5, 2000. [PMID: 11054200]
11. Watson NT, Weiss EL, Harter PM: Famotidine in the treatment of acute urticaria. *Clin Exp Dermatol* 26: 3, 2000. [PMID: 11260167]
12. Vena GA: Clobetasol propionate 0.05% in a novel foam formulation is safe and effective in the short-term treatment of patients with delayed pressure urticaria. A randomized, double-blind, placebo-controlled trial. *Br J Dermatol* 154: 2, 2006. [PMID: 16433809]
13. Melian EB: Clobetasol propionate foam, 0.05%. *Am J Clin Dermatol* 2: 89, 2001. [PMID: 11705308]
14. Thierry A: Conversion of L-leucine to isovaleric acid by *Propionibacterium freudenreichii* TL 34 and IPGP23. *Appl Environ Microbiol* 68: 2, 2002. [PMID: 11823198]
15. Lin M: “Toxic sock syndrome” tricks of the trade. ACEP News, November 2006 p. 7.